Morphle Labs, a Bengaluru-based deep-tech healthcare automation company, has raised $5 million in a Series A funding round by Inflexor Ventures.
The funds raised will be used to scale manufacturing to meet accelerating global demand for RoboTome and MorphoLens, expand its IP portfolio across international jurisdictions, and push forward on global regulatory certifications essential for medical device commercialisation.
The company also plans to grow its engineering, research, and product teams across robotics, vision systems, optics, hardware development, medical-grade software, and compliance.
Founded in 2017 by Rohit Hiwale, Morphle Labs is a deep-tech healthcare automation company building robotic and imaging systems for cancer diagnostics.
Morphle Labs is addressing one of the most underserved but critical aspects of healthcare: automation in histopathology, the core of cancer diagnostics.
The company’s flagship platform, RoboTome, is the first robotic microtome of its kind, capable of slicing biopsy blocks at over twice the speed of an experienced histotechnologist while delivering unmatched consistency in section quality, a critical requirement for downstream diagnostics. Its complementary platform, MorphoLens, is a high-throughput slide scanner that digitises 100+ slides per hour through robust optics and AI-driven imaging, enabling remote pathology and scalable diagnostic operations. Together, the platforms automate some of the most complex and historically manual steps in histology, forming an end-to-end workflow that improves speed, reliability, and clinical readiness. Morphle has filed 80+ patents across robotics, optics, embedded systems, and imaging, underscoring its deep R&D culture.
Beyond its current platforms, Morphle is building integrated automation layers across the tissue diagnostics workflow, creating a seamless, AI and robotics-powered pipeline that could significantly reduce diagnostic turnaround times and improve outcomes for cancer patients worldwide.
Morphle’s 100-member team is based primarily in Bengaluru and Boston, with an expanding commercial presence in the U.S. and Europe.
Rohit Hiwale, Founder & CEO, Morphle Labs, said, “Our vision at Morphle is to rethink healthcare from the ground up. Histology remains one of the few critical domains still untouched by true automation, and that is where we have chosen to start. With RoboTome and MorphoLens, we have tackled two of the most challenging bottlenecks in diagnostics, high-throughput robotic microtomy and robust, modular slide imaging, but this is only the beginning. The larger opportunity lies in stitching together every broken link in the diagnostics chain, enabling labs to deliver faster, higher-quality results and empowering pathologists to focus on what matters most: the diagnosis.”
Pratip Mazumdar, Partner at Inflexor Ventures, said, “Morphle Labs is transforming one of the most overlooked yet mission-critical segments of global healthcare. Their ability to bring together robotics, imaging, and AI into clinically reliable systems is exceptional. The traction they are already seeing with leading labs in the U.S. and Europe demonstrates both the scale of the problem and Morphle’s ability to solve it. We believe they are poised to become a global leader in tissue diagnostics automation, and we are excited to support their journey.”
